{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "32126112", "DateCompleted": {"Year": "2020", "Month": "06", "Day": "16"}, "DateRevised": {"Year": "2024", "Month": "04", "Day": "23"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "03", "Day": "03"}], "Language": ["eng"], "ELocationID": ["e0229646", "10.1371/journal.pone.0229646"], "Journal": {"ISSN": "1932-6203", "JournalIssue": {"Volume": "15", "Issue": "3", "PubDate": {"Year": "2020"}}, "Title": "PloS one", "ISOAbbreviation": "PLoS One"}, "ArticleTitle": "Evaluating kratom alkaloids using PHASE.", "Pagination": {"StartPage": "e0229646", "MedlinePgn": "e0229646"}, "Abstract": {"AbstractText": ["Kratom is a botanical substance that is marketed and promoted in the US for pharmaceutical opioid indications despite having no US Food and Drug Administration approved uses. Kratom contains over forty alkaloids including two partial agonists at the mu opioid receptor, mitragynine and 7-hydroxymitragynine, that have been subjected to the FDA's scientific and medical evaluation. However, pharmacological and toxicological data for the remaining alkaloids are limited. Therefore, we applied the Public Health Assessment via Structural Evaluation (PHASE) protocol to generate in silico binding profiles for 25 kratom alkaloids to facilitate the risk evaluation of kratom. PHASE demonstrates that kratom alkaloids share structural features with controlled opioids, indicates that several alkaloids bind to the opioid, adrenergic, and serotonin receptors, and suggests that mitragynine and 7-hydroxymitragynine are the strongest binders at the mu opioid receptor. Subsequently, the in silico binding profiles of a subset of the alkaloids were experimentally verified at the opioid, adrenergic, and serotonin receptors using radioligand binding assays. The verified binding profiles demonstrate the ability of PHASE to identify potential safety signals and provide a tool for prioritizing experimental evaluation of high-risk compounds."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, United States of America."}], "LastName": "Ellis", "ForeName": "Christopher R", "Initials": "CR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, United States of America."}], "LastName": "Racz", "ForeName": "Rebecca", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, United States of America."}], "LastName": "Kruhlak", "ForeName": "Naomi L", "Initials": "NL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, United States of America."}], "LastName": "Kim", "ForeName": "Marlene T", "Initials": "MT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America."}], "LastName": "Zakharov", "ForeName": "Alexey V", "Initials": "AV"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America."}], "LastName": "Southall", "ForeName": "Noel", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Controlled Substances Staff, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, United States of America."}], "LastName": "Hawkins", "ForeName": "Edward G", "Initials": "EG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, United States of America."}], "LastName": "Burkhart", "ForeName": "Keith", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, United States of America."}], "LastName": "Strauss", "ForeName": "David G", "Initials": "DG"}, {"Identifier": ["0000-0002-6307-2314"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, United States of America."}], "LastName": "Stavitskaya", "ForeName": "Lidiya", "Initials": "L"}], "GrantList": [{"GrantID": "ZIA TR000058", "Acronym": "ImNIH", "Agency": "Intramural NIH HHS", "Country": "United States"}, {"GrantID": "HHSN271201800023C", "Acronym": "DA", "Agency": "NIDA NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, N.I.H., Intramural", "Research Support, U.S. Gov't, Non-P.H.S.", "Research Support, U.S. Gov't, P.H.S."]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "PLoS One", "NlmUniqueID": "101285081", "ISSNLinking": "1932-6203"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Receptors, Adrenergic"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Opioid"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Opioid, mu"}, {"RegistryNumber": "0", "NameOfSubstance": "Receptors, Serotonin"}, {"RegistryNumber": "0", "NameOfSubstance": "Secologanin Tryptamine Alkaloids"}, {"RegistryNumber": "EP479K822J", "NameOfSubstance": "mitragynine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Binding Sites"}, {"QualifierName": [], "DescriptorName": "HEK293 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "In Vitro Techniques"}, {"QualifierName": ["chemistry"], "DescriptorName": "Mitragyna"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Radioligand Assay"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Receptors, Adrenergic"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Receptors, Opioid"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Receptors, Opioid, mu"}, {"QualifierName": ["drug effects", "metabolism"], "DescriptorName": "Receptors, Serotonin"}, {"QualifierName": ["chemistry", "pharmacokinetics", "pharmacology"], "DescriptorName": "Secologanin Tryptamine Alkaloids"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "This work was performed as part of a Research Collaboration Agreement between the FDA and Chemotargets SL, Barcelona, Spain. The findings and conclusions in this article reflect the views of the authors and should not be construed to represent the FDA's views or policies. The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ellis CR, Racz R, Kruhlak NL, Kim MT, Hawkins EG, Strauss DG, et al. Assessing the Structural and Pharmacological Similarity of Newly Identified Drugs of Abuse to Controlled Substances using PHASE. Clin Pharmacol Ther. 2019;106(1):116\u201322. 10.1002/cpt.1418", "ArticleIdList": ["10.1002/cpt.1418", "PMC6617983", "30957872"]}, {"Citation": "Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792\u20139. Epub 2012/12/06. .", "ArticleIdList": ["23212430"]}, {"Citation": "Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27(3):21\u20137. Epub 1975/07/01. .", "ArticleIdList": ["1041694"]}, {"Citation": "Anwar M, Law R, Schier J. Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers\u2014United States, 2010\u20132015. MMWR Morb Mortal Wkly Rep. 2016;65(29):748\u20139. Epub 2016/07/29. 10.15585/mmwr.mm6529a4 .", "ArticleIdList": ["10.15585/mmwr.mm6529a4", "27466822"]}, {"Citation": "Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, et al. Following \"the Roots\" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. Biomed Res Int. 2015;2015:968786 Epub 2015/12/08. 10.1155/2015/968786", "ArticleIdList": ["10.1155/2015/968786", "PMC4657101", "26640804"]}, {"Citation": "Grundmann O. Patterns of Kratom use and health impact in the US-Results from an online survey. Drug Alcohol Depend. 2017;176:63\u201370. Epub 2017/05/19. 10.1016/j.drugalcdep.2017.03.007 .", "ArticleIdList": ["10.1016/j.drugalcdep.2017.03.007", "28521200"]}, {"Citation": "Yue K, Kopajtic TA, Katz JL. Abuse liability of mitragynine assessed with a self-administration procedure in rats. Psychopharmacology (Berl). 2018;235(10):2823\u20139. Epub 2018/07/25. 10.1007/s00213-018-4974-9 .", "ArticleIdList": ["10.1007/s00213-018-4974-9", "30039246"]}, {"Citation": "Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2018. Epub 2018/06/28. 10.1111/adb.12639 .", "ArticleIdList": ["10.1111/adb.12639", "29949228"]}, {"Citation": "Kamble SH, Sharma A, King TI, Leon F, McCurdy CR, Avery BA. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). Xenobiotica. 2018:1\u201331. Epub 2018/12/15. 10.1080/00498254.2018.1552819 .", "ArticleIdList": ["10.1080/00498254.2018.1552819", "30547698"]}, {"Citation": "Singh D, Muller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132\u20137. Epub 2014/04/05. 10.1016/j.drugalcdep.2014.03.017 .", "ArticleIdList": ["10.1016/j.drugalcdep.2014.03.017", "24698080"]}, {"Citation": "Yusoff NH, Suhaimi FW, Vadivelu RK, Hassan Z, Rumler A, Rotter A, et al. Abuse potential and adverse cognitive effects of mitragynine (kratom). Addict Biol. 2016;21(1):98\u2013110. Epub 2014/09/30. 10.1111/adb.12185 .", "ArticleIdList": ["10.1111/adb.12185", "25262913"]}, {"Citation": "Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, Ponglux D, et al. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2004;74(17):2143\u201355. Epub 2004/02/19. 10.1016/j.lfs.2003.09.054 .", "ArticleIdList": ["10.1016/j.lfs.2003.09.054", "14969718"]}, {"Citation": "Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. J Med Toxicol. 2016;12(4):341\u20139. Epub 2016/10/19. 10.1007/s13181-016-0588-y", "ArticleIdList": ["10.1007/s13181-016-0588-y", "PMC5135684", "27752985"]}, {"Citation": "Adkins JE, Boyer EW, McCurdy CR. Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Curr Top Med Chem. 2011;11(9):1165\u201375. 10.2174/156802611795371305 .", "ArticleIdList": ["10.2174/156802611795371305", "21050173"]}, {"Citation": "Leon F, Habib E, Adkins JE, Furr EB, McCurdy CR, Cutler SJ. Phytochemical characterization of the leaves of Mitragyna speciosa grown in U.S.A. Nat Prod Commun. 2009;4(7):907\u201310. Epub 2009/09/08. .", "ArticleIdList": ["PMC9255435", "19731590"]}, {"Citation": "Avery BA, Boddu SP, Sharma A, Furr EB, Leon F, Cutler SJ, et al. Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats. Planta Med. 2018. Epub 2018/11/20. 10.1055/a-0770-3683 .", "ArticleIdList": ["10.1055/a-0770-3683", "30452072"]}, {"Citation": "Kruegel AC, Gassaway MM, Kapoor A, Varadi A, Majumdar S, Filizola M, et al. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. J Am Chem Soc. 2016;138(21):6754\u201364. 10.1021/jacs.6b00360", "ArticleIdList": ["10.1021/jacs.6b00360", "PMC5189718", "27192616"]}, {"Citation": "Pfleger KD, Seeber RM, Eidne KA. Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions. Nat Protoc. 2006;1(1):337\u201345. Epub 2007/04/05. 10.1038/nprot.2006.52 .", "ArticleIdList": ["10.1038/nprot.2006.52", "17406254"]}, {"Citation": "Clayton CC, Donthamsetti P, Lambert NA, Javitch JA, Neve KA. Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor. J Biol Chem. 2014;289(48):33663\u201375. Epub 2014/10/23. 10.1074/jbc.M114.605378", "ArticleIdList": ["10.1074/jbc.M114.605378", "PMC4246117", "25336643"]}, {"Citation": "Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018;134(Pt A):108\u201320. Epub 2017/08/24. 10.1016/j.neuropharm.2017.08.026 .", "ArticleIdList": ["10.1016/j.neuropharm.2017.08.026", "28830758"]}, {"Citation": "Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013;37(2):138\u201351. Epub 2012/12/05. 10.1016/j.neubiorev.2012.11.012 .", "ArticleIdList": ["10.1016/j.neubiorev.2012.11.012", "23206666"]}, {"Citation": "Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem Substance and Compound databases. Nucleic Acids Res. 2016;44(D1):D1202\u201313. Epub 2015/09/25. 10.1093/nar/gkv951", "ArticleIdList": ["10.1093/nar/gkv951", "PMC4702940", "26400175"]}, {"Citation": "Molecular Operating Environment (MOE). Chemical Conputing Group Inc, 20151001 1010 Sherbooke St West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2017."}, {"Citation": "Williams C. Reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance. Mol Divers. 2006;10(3):311\u201332. Epub 2006/10/13. 10.1007/s11030-006-9039-z .", "ArticleIdList": ["10.1007/s11030-006-9039-z", "17031535"]}, {"Citation": "Willett P. Chemical Similarity Search. J Chem Inf Comput Sci. 1998;38:983\u201396."}, {"Citation": "Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197\u2013206. 10.1038/nbt1284 .", "ArticleIdList": ["10.1038/nbt1284", "17287757"]}, {"Citation": "Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175\u201381. 10.1038/nature08506", "ArticleIdList": ["10.1038/nature08506", "PMC2784146", "19881490"]}, {"Citation": "Garcia-Serna R, Vidal D, Remez N, Mestres J. Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms. Chem Res Toxicol. 2015;28(10):1875\u201387. Epub 2015/09/12. 10.1021/acs.chemrestox.5b00260 .", "ArticleIdList": ["10.1021/acs.chemrestox.5b00260", "26360911"]}, {"Citation": "Vidal D, Mestres J. In Silico Receptorome Screening of Antipsychotic Drugs. Mol Inform. 2010;29(6\u20137):543\u201351. Epub 2010/07/12. 10.1002/minf.201000055 .", "ArticleIdList": ["10.1002/minf.201000055", "27463332"]}, {"Citation": "Ellis CR, Kruhlak NL, Kim MT, Hawkins EG, Stavitskaya L. Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking. PLoS One. 2018;13(5):e0197734 Epub 2018/05/26. 10.1371/journal.pone.0197734", "ArticleIdList": ["10.1371/journal.pone.0197734", "PMC5967713", "29795628"]}, {"Citation": "Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, et al. Structural insights into micro-opioid receptor activation. Nature. 2015;524(7565):315\u201321. 10.1038/nature14886", "ArticleIdList": ["10.1038/nature14886", "PMC4639397", "26245379"]}, {"Citation": "Jakalian A, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem. 2002;23(16):1623\u201341. 10.1002/jcc.10128 .", "ArticleIdList": ["10.1002/jcc.10128", "12395429"]}, {"Citation": "Gerber PR, Muller K. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J Comput Aided Mol Des. 1995;9(3):251\u201368. 10.1007/bf00124456 .", "ArticleIdList": ["10.1007/bf00124456", "7561977"]}, {"Citation": "Case DA, Betz RM, Botello-Smith W, Cerutti DS, T.E. Cheatham I, Darden TA, et al. AMBER 2016. 2016;University of California, San Fransico."}, {"Citation": "Corbeil CR, Williams CI, Labute P. Variability in docking success rates due to dataset preparation. J Comput Aided Mol Des. 2012;26(6):775\u201386. 10.1007/s10822-012-9570-1", "ArticleIdList": ["10.1007/s10822-012-9570-1", "PMC3397132", "22566074"]}, {"Citation": "Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, et al. Automated design of ligands to polypharmacological profiles. Nature. 2012;492(7428):215\u201320. Epub 2012/12/14. 10.1038/nature11691", "ArticleIdList": ["10.1038/nature11691", "PMC3653568", "23235874"]}, {"Citation": "Roth BL. National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) Assay Protocol Book2018 March 2018."}, {"Citation": "Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103(6):1048\u201350. Epub 2008/05/17. 10.1111/j.1360-0443.2008.02209.x", "ArticleIdList": ["10.1111/j.1360-0443.2008.02209.x", "PMC3670991", "18482427"]}, {"Citation": "Tay YL, Teah YF, Chong YM, Jamil MFA, Kollert S, Adenan MI, et al. Mitragynine and its potential blocking effects on specific cardiac potassium channels. Toxicol Appl Pharmacol. 2016;305:22\u201339. Epub 2016/06/05. 10.1016/j.taap.2016.05.022 .", "ArticleIdList": ["10.1016/j.taap.2016.05.022", "27260674"]}, {"Citation": "Khan ZP, Ferguson CN, Jones RM. alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999;54(2):146\u201365. Epub 1999/04/24. 10.1046/j.1365-2044.1999.00659.x .", "ArticleIdList": ["10.1046/j.1365-2044.1999.00659.x", "10215710"]}, {"Citation": "Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 2017;31(9):1091\u2013120. Epub 2017/09/01. 10.1177/0269881117725915", "ArticleIdList": ["10.1177/0269881117725915", "PMC5606297", "28858536"]}, {"Citation": "Panczyk K, Golda S, Waszkielewicz A, Zelaszczyk D, Gunia-Krzyzak A, Marona H. Serotonergic system and its role in epilepsy and neuropathic pain treatment: a review based on receptor ligands. Curr Pharm Des. 2015;21(13):1723\u201340. Epub 2014/11/22. 10.2174/1381612821666141121114917 .", "ArticleIdList": ["10.2174/1381612821666141121114917", "25412650"]}, {"Citation": "Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature. 2012;485(7398):321\u20136. Epub 2012/03/23. 10.1038/nature10954", "ArticleIdList": ["10.1038/nature10954", "PMC3523197", "22437502"]}, {"Citation": "Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785\u201391. Epub 2009/04/29. 10.1002/jcc.21256", "ArticleIdList": ["10.1002/jcc.21256", "PMC2760638", "19399780"]}, {"Citation": "Pantsar T, Poso A. Binding Affinity via Docking: Fact and Fiction. Molecules. 2018;23(8). Epub 2018/08/01. 10.3390/molecules23081899", "ArticleIdList": ["10.3390/molecules23081899", "PMC6222344", "30061498"]}, {"Citation": "Yeadon M, Kitchen I. Differences in the characteristics of opioid receptor binding in the rat and marmoset. J Pharm Pharmacol. 1988;40(10):736\u20139. 10.1111/j.2042-7158.1988.tb07008.x .", "ArticleIdList": ["10.1111/j.2042-7158.1988.tb07008.x", "2907546"]}, {"Citation": "Varadi A, Marrone GF, Palmer TC, Narayan A, Szabo MR, Le Rouzic V, et al. Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit beta-Arrestin-2. J Med Chem. 2016;59(18):8381\u201397. 10.1021/acs.jmedchem.6b00748 .", "ArticleIdList": ["10.1021/acs.jmedchem.6b00748", "PMC5344672", "27556704"]}, {"Citation": "Roberts MF, Wink M. Alkaloids: Biochemistry, ecology, and medicinal applications New York: Plenum Press; 1998."}], "ReferenceList": []}], "History": [{"Year": "2019", "Month": "7", "Day": "23"}, {"Year": "2020", "Month": "2", "Day": "11"}, {"Year": "2020", "Month": "3", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "3", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "6", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "3", "Day": "3"}], "PublicationStatus": "epublish", "ArticleIdList": ["32126112", "PMC7053747", "10.1371/journal.pone.0229646", "PONE-D-19-20744"]}}], "PubmedBookArticle": []}